Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue from product sales	$ 0	$ 12
Collaboration revenue	0	4
Total revenue	0	16
Cost of product sales	0	17
Cost of collaboration revenue	0	1
Total cost of revenue	0	18
Gross loss	0	(2)
Research and development expense	1,464	2,602
Selling, general and administrative expense	1,481	2,740
Operating loss	(4,454)	(6,668)
Other income (expense):
Warrant revaluation income (expense)	(46)	5,257
Derivative revaluation expense	(312)	0
Interest expense	(183)	0
Interest Income (Expense), Net	(12)	4
Loss before income taxes	(5,007)	(1,407)
Income tax benefit	0	0
Net loss	(5,007)	(1,407)
Dividend paid in-kind to preferred stockholders	(20)	0
Deemed dividend on preferred stock (see Note 10)	(3,734)	0
Net loss attributable to common stockholders	$ (8,761)	$ (1,407)
Per Share Information:
Basic net loss (usd per share)	$ (0.60)	$ (0.10)
Diluted net loss (usd per share)	$ (0.60)	$ (0.23)
Weighted average number of common shares outstanding:
Basic weighted average number of common shares outstanding (shares)	14,694,613	14,632,988
Diluted weighted average number of common shares outstanding (shares)	14,697,210	14,657,011
Affiliated Entity
Research and development expense	$ 1,509	$ 1,324